Carl Zeiss Meditec AG has received FDA clearance for its PLEX Elite 9000 Swept-Source OCT posterior ocular imaging system, expanding the potential for clinical researchers to open new frontiers of discovery in diseases affecting the retina. The PLEX Elite 9000 offers researchers the potential to assess early mechanisms for micro- and neovascularization, explore the progression of retinal and choroidal pathology, deepen the understanding of choroid physiopathology and to evaluate mechanisms of retina and choroid response to therapy. The wide-field high-resolution visualization provided by the platform expands clinicians’ ability to examine the critical microstructures and microvasculature of the posterior segment at any depth of interest from vitreous to sclera. Carl Zeiss Meditec is a medical technology company that supplies innovative technologies and application-oriented solutions.